Infective Complications in TP Biopsy Without Antibiotic Prophylaxis
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 8, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the risk of infections after a specific type of prostate biopsy called a transperineal biopsy, which is done through the skin between the scrotum and the anus. The unique part of this study is that it will look at the outcomes for patients who do not receive antibiotics before the procedure, compared to previous data where patients did receive antibiotics. The goal is to understand if skipping antibiotics affects the chance of developing infections after the biopsy.
To participate in this trial, men aged 65 to 74 who are undergoing this type of biopsy for reasons like having a high PSA level, an abnormal digital rectal exam (DRE), or needing a follow-up biopsy may be eligible. However, certain individuals, such as those with recent urinary tract infections or specific health conditions like a weakened immune system, will not be able to join. If you decide to participate, you will be monitored for any signs of infection after the biopsy, helping researchers gather important information that could influence future treatment practices.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- * All consecutive patients in participating centres receiving transperineal USG-guided biopsy for any indication including:
- • Elevated PSA
- • Abnormal DRE
- • Follow-up biopsy in active surveillance
- • Suspicion of CAP recurrence after radiotherapy
- • Follow-up biopsy after focal therapy
- • Consenting to the study
- Exclusion Criteria:
- • Recent suspected UTI within 1 month
- • Recent culture proven bacteriuria within 1 month
- • History of recurrent UTI
- • Indwelling urinary catheter
- • Immunocompromised state
- • High risk of infective endocarditis (including prosthetic heart valve, congenital heart disease, or previous history of infective endocarditis
- • Incompetent or incapable of understanding the nature of the study or giving informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, , Hong Kong
Patients applied
Trial Officials
Peter Ka-Fung CHIU, PhD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported